105 related articles for article (PubMed ID: 38735754)
1. Impact of Hepatitis B Surface and Core Antibody Levels on Hepatitis B Virus Reactivation.
Ohkubo M; Seo E; Doki K; Suzuki Y; Sekine I; Homma M
Biol Pharm Bull; 2024; 47(5):941-945. PubMed ID: 38735754
[TBL] [Abstract][Full Text] [Related]
2. Reactivation of hepatitis B virus infection following rituximab treatment in HBsAg-negative, HBcAb-positive rheumatoid arthritis patients: A long-term, real-world observation.
Chen YM; Chen HH; Huang WN; Chen YH; Hsieh TY; Yang SS; Lan JL; Chen DY
Int J Rheum Dis; 2019 Jun; 22(6):1145-1151. PubMed ID: 31117160
[TBL] [Abstract][Full Text] [Related]
3. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis.
Koo YX; Tay M; Teh YE; Teng D; Tan DS; Tan IB; Tai DW; Quek R; Tao M; Lim ST
Ann Hematol; 2011 Oct; 90(10):1219-23. PubMed ID: 21520001
[TBL] [Abstract][Full Text] [Related]
4. High titers of anti-HBs prevent rituximab-related viral reactivation in resolved hepatitis B patient with non-Hodgkin's lymphoma.
Cho Y; Yu SJ; Cho EJ; Lee JH; Kim TM; Heo DS; Kim YJ; Yoon JH
J Med Virol; 2016 Jun; 88(6):1010-7. PubMed ID: 26531242
[TBL] [Abstract][Full Text] [Related]
5. Association of Hepatitis B Core-Related Antigen With Hepatitis B Virus Reactivation in Occult Viral Carriers Undergoing High-Risk Immunosuppressive Therapy.
Seto WK; Wong DK; Chan TS; Hwang YY; Fung J; Liu KS; Gill H; Lam YF; Cheung KS; Lie AK; Lai CL; Kwong YL; Yuen MF
Am J Gastroenterol; 2016 Dec; 111(12):1788-1795. PubMed ID: 27644733
[TBL] [Abstract][Full Text] [Related]
6. Clinical and virological factors associated with hepatitis B virus reactivation in HBsAg-negative and anti-HBc antibodies-positive patients undergoing chemotherapy and/or autologous stem cell transplantation for cancer.
Borentain P; Colson P; Coso D; Bories E; Charbonnier A; Stoppa AM; Auran T; Loundou A; Motte A; Ressiot E; Norguet E; Chabannon C; Bouabdallah R; Tamalet C; Gérolami R
J Viral Hepat; 2010 Nov; 17(11):807-15. PubMed ID: 20002298
[TBL] [Abstract][Full Text] [Related]
7. Improving testing for hepatitis B before treatment with rituximab.
Dyson JK; Jopson L; Ng S; Lowery M; Harwood J; Waugh S; Valappil M; McPherson S
Eur J Gastroenterol Hepatol; 2016 Oct; 28(10):1172-8. PubMed ID: 27388147
[TBL] [Abstract][Full Text] [Related]
8. Changes in hepatitis B virus surface antibody titer and risk of hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients undergoing biologic therapy for rheumatic diseases: a prospective cohort study.
Tien YC; Yen HH; Li CF; Liu MP; Hsue YT; Hung MH; Chiu YM
Arthritis Res Ther; 2018 Nov; 20(1):246. PubMed ID: 30382902
[TBL] [Abstract][Full Text] [Related]
9. Determining Whether Prophylactic Antiviral Treatment Is Necessary in HBsAg-Negative/HBcAb-Positive Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation.
Zhang A; Wu Y; Tan Y; Shi J; Zhao Y; Hu Y; Yu J; Zheng W; Lai X; Zhang M; Zhu Y; Ye Y; Huang Y; Fu S; Huang H; Luo Y
Biol Blood Marrow Transplant; 2020 May; 26(5):956-964. PubMed ID: 31962163
[TBL] [Abstract][Full Text] [Related]
10. Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/ HBcAb-positive: a multicenter retrospective study.
Ji D; Cao J; Hong X; Li J; Wang J; Chen F; Wang C; Zou S
Eur J Haematol; 2010 Sep; 85(3):243-50. PubMed ID: 20491883
[TBL] [Abstract][Full Text] [Related]
11. Management of the HBV reactivation in isolated HBcAb positive patients affected with Non Hodgkin Lymphoma.
Masarone M; De Renzo A; La Mura V; Sasso FC; Romano M; Signoriello G; Rosato V; Perna F; Pane F; Persico M
BMC Gastroenterol; 2014 Feb; 14():31. PubMed ID: 24533834
[TBL] [Abstract][Full Text] [Related]
12. Reverse seroconversion of hepatitis B virus after hematopoietic stem cell transplantation.
Goyama S; Kanda Y; Nannya Y; Kawazu M; Takeshita M; Niino M; Komeno Y; Nakamoto T; Kurokawa M; Tsujino S; Ogawa S; Aoki K; Chiba S; Motokura T; Shiratori Y; Hirai H
Leuk Lymphoma; 2002 Nov; 43(11):2159-63. PubMed ID: 12533042
[TBL] [Abstract][Full Text] [Related]
13. Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infection.
Yang HC; Tsou HH; Pei SN; Chang CS; Chen JH; Yao M; Lin SJ; Lin J; Yuan Q; Xia N; Liu TW; Chen PJ; Cheng AL; Hsu C;
J Hepatol; 2018 Aug; 69(2):286-292. PubMed ID: 29551710
[TBL] [Abstract][Full Text] [Related]
14. HBV reactivation risk factors in patients with chronic HBV infection with low replicative state and resolved HBV infection undergoing hematopoietic stem cell transplantation in Korea.
Jun CH; Kim BS; Oak CY; Lee DH; Cho E; Cho SB; Choi SK; Park CH; Joo YE; Lee JJ; Kim HJ
Hepatol Int; 2017 Jan; 11(1):87-95. PubMed ID: 27351765
[TBL] [Abstract][Full Text] [Related]
15. Incidence of hepatitis B virus reactivation in patients with resolved infection on immunosuppressive therapy for rheumatic disease: a multicentre, prospective, observational study in Japan.
Fukuda W; Hanyu T; Katayama M; Mizuki S; Okada A; Miyata M; Handa Y; Hayashi M; Koyama Y; Arii K; Kitaori T; Hagiyama H; Urushidani Y; Yamasaki T; Ikeno Y; Suzuki T; Omoto A; Sugitani T; Morita S; Inokuma S
Ann Rheum Dis; 2017 Jun; 76(6):1051-1056. PubMed ID: 27934678
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis.
Harigai M; Winthrop K; Takeuchi T; Hsieh TY; Chen YM; Smolen JS; Burmester G; Walls C; Wu WS; Dickson C; Liao R; Genovese MC
RMD Open; 2020 Feb; 6(1):. PubMed ID: 32098857
[TBL] [Abstract][Full Text] [Related]
17. Late HBsAg seroreversion of mutated hepatitis B virus after bone marrow transplantation.
Schubert A; Michel D; Mertens T
BMC Infect Dis; 2013 May; 13():223. PubMed ID: 23679074
[TBL] [Abstract][Full Text] [Related]
18. HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb.
Sarrecchia C; Cappelli A; Aiello P
J Infect Chemother; 2005 Aug; 11(4):189-91. PubMed ID: 16133710
[TBL] [Abstract][Full Text] [Related]
19. HBsAg (-)/HBsAb (-)/HBeAg (-)/HBeAb (+)/HBcAb (+) predicts a high risk of hepatitis B reactivation in patients with B-cell lymphoma receiving rituximab based immunochemotherapy.
Shui LP; Zhu Y; Duan XQ; Chen YT; Yang L; Tang XQ; Zhang HB; Xiao Q; Wang L; Liu L; Luo XH
J Med Virol; 2023 Feb; 95(2):e28549. PubMed ID: 36734081
[TBL] [Abstract][Full Text] [Related]
20. Effects of rituximab dose on hepatitis B reactivation in patients with resolved infection undergoing immunologic incompatible kidney transplantation.
Lee J; Park JY; Kim DG; Lee JY; Kim BS; Kim MS; Il Kim S; Kim YS; Huh KH
Sci Rep; 2018 Oct; 8(1):15629. PubMed ID: 30353021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]